vTv Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

§ 01 Executive Snapshot

• What: vTv Therapeutics reports Q1 2026 financial results and progress on the Phase 3 CATT1 trial.
• Who: vTv Therapeutics Inc., Paul Sekhri (Chairman, President, and CEO).
• Why it matters: The company's advancements in cadisegliatin treatment for type 1 diabetes could influence the future of diabetes management and the company's financial health.

§ 02 Key Developments

• Enrollment in the Phase 3 CATT1 trial for cadisegliatin is on track for completion in Q3 2026.
• vTv Therapeutics received a $20 million upfront payment from Newsoara Biopharma as part of a license amendment and could earn up to $115 million in milestones and royalties.
• Cash and cash equivalents increased to $98.1 million as of March 31, 2026, compared to $88.9 million at the end of 2025.

§ 03 Strategic Context

• vTv Therapeutics is focused on developing cadisegliatin, a potential first-in-class oral therapy for type 1 diabetes, amidst a competitive biopharmaceutical landscape.
• The completion of the CATT1 trial and subsequent data readout are pivotal moments that could significantly affect the company's valuation and market position.

§ 04 Strategic Implications

• The successful completion of the CATT1 trial could lead to increased investor confidence and potentially higher stock valuation for vTv Therapeutics.
• The company's strengthened balance sheet positions it well for future clinical developments and operational sustainability.

§ 05 Risks & Constraints

• Potential risks include regulatory hurdles associated with the approval of cadisegliatin and competition from other diabetes treatments.
• Execution risks related to trial enrollment and data collection could impact timelines and results.

§ 06 Watchlist / Forward Signals

• The anticipated topline data readout from the CATT1 trial is expected in late 2026 and will be crucial for the company’s strategic direction.
• Upcoming investor conferences in May 2026 will provide insights into investor sentiment and potential market reactions to the company's progress.